Literature DB >> 7485538

Increased sensitivity of the renal vasculature to adenosine in streptozotocin-induced diabetes mellitus rats.

A C Pflueger1, F Schenk, H Osswald.   

Abstract

Adenosine (ADO) has been implicated as a pathophysiological factor in contrast media (CM)-induced acute renal failure, which has been encountered more often in patients with diabetes and impaired renal function. Therefore, we studied the renal vascular response to exogenous and endogenous ADO in streptozotocin-induced diabetic rats. We found that exogenous ADO (0.01-100 nmol), injected into the abdominal aorta, decreased renal blood flow (RBF) in a dose-dependent manner. The dose-response curve was shifted to the left by factor 30 in diabetic, compared with nondiabetic rats rats. Renal vascular response to endogenous ADO, assessed by postocclusive reduction of RBF after a 30-s renal artery occlusion, was significantly enhanced (P < 0.001) in diabetic rats (75.6 +/- 3.9%) compared with nondiabetic rats (36.5 +/- 2%). ADO A1-receptor blockade with 8-cyclopentyl-1,3-dipropylxanthine attenuated exogenous and endogenous ADO-induced renal vasoconstriction in both groups. We conclude that the ADO A1-receptor signal-transduction chain is altered in diabetic animals and that the enhanced vasoconstrictive action of ADO could be involved in the kidney pathophysiology of diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7485538     DOI: 10.1152/ajprenal.1995.269.4.F529

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  12 in total

Review 1.  Contrast-induced acute kidney injury and diabetic nephropathy.

Authors:  Andrew D Calvin; Sanjay Misra; Axel Pflueger
Journal:  Nat Rev Nephrol       Date:  2010-09-28       Impact factor: 28.314

2.  Region-specific alterations of adenosine receptors expression level in kidney of diabetic rat.

Authors:  Tadeusz Pawelczyk; Marzena Grden; Robert Rzepko; Monika Sakowicz; Andrzej Szutowicz
Journal:  Am J Pathol       Date:  2005-08       Impact factor: 4.307

3.  Adenosine formed by 5'-nucleotidase mediates tubuloglomerular feedback.

Authors:  S Thomson; D Bao; A Deng; V Vallon
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

Review 4.  Alteration of purinergic signaling in diabetes: Focus on vascular function.

Authors:  Rui Zhou; Xitong Dang; Randy S Sprague; S Jamal Mustafa; Zhichao Zhou
Journal:  J Mol Cell Cardiol       Date:  2020-02-11       Impact factor: 5.000

5.  Renal haemodynamic responses to exogenous and endogenous adenosine in conscious dogs.

Authors:  H Berthold; A Just; H R Kirchheim; H Osswald; H Ehmke
Journal:  J Physiol       Date:  1998-07-01       Impact factor: 5.182

6.  Angiotensin II contributes to glomerular hyperfiltration in diabetic rats independently of adenosine type I receptors.

Authors:  Daniela Patinha; Angelica Fasching; Dora Pinho; António Albino-Teixeira; Manuela Morato; Fredrik Palm
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-02

Review 7.  Acute Kidney Injury and Progression of Diabetic Kidney Disease.

Authors:  Samuel Mon-Wei Yu; Joseph V Bonventre
Journal:  Adv Chronic Kidney Dis       Date:  2018-03       Impact factor: 3.620

8.  Insulin restores expression of adenosine kinase in streptozotocin-induced diabetes mellitus rats.

Authors:  Monika Sakowicz; Tadeusz Pawelczyk
Journal:  Mol Cell Biochem       Date:  2002-07       Impact factor: 3.396

9.  Lack of A1 adenosine receptors augments diabetic hyperfiltration and glomerular injury.

Authors:  Robert Faulhaber-Walter; Limeng Chen; Mona Oppermann; Soo Mi Kim; Yuning Huang; Noriyuki Hiramatsu; Diane Mizel; Hiroshi Kajiyama; Patricia Zerfas; Josephine P Briggs; Jeffrey B Kopp; Jurgen Schnermann
Journal:  J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 10.121

10.  Multi-factor analysis of failure of renal replacement therapy in acute renal failure developed after cardiac surgery.

Authors:  Pawel Nawrocki; Ireneusz Szwedo; Joanna Tyc; Anna Hawrysz; Kamila Janiak; Romuald Cichoń
Journal:  Kardiochir Torakochirurgia Pol       Date:  2015-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.